Baxter International Inc (BAX) Stake Decreased by Hartford Investment Management Co.

Hartford Investment Management Co. lowered its holdings in Baxter International Inc (NYSE:BAX) by 1.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 58,326 shares of the medical instruments supplier’s stock after selling 623 shares during the quarter. Hartford Investment Management Co.’s holdings in Baxter International were worth $4,742,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of BAX. Norges Bank acquired a new position in Baxter International during the 4th quarter worth $549,458,000. Morgan Stanley lifted its holdings in Baxter International by 267.9% during the 3rd quarter. Morgan Stanley now owns 10,570,520 shares of the medical instruments supplier’s stock worth $814,880,000 after buying an additional 7,697,267 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Baxter International by 6,487.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 3,555,596 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 3,501,620 shares during the last quarter. Standard Life Aberdeen plc lifted its holdings in Baxter International by 121.2% during the 3rd quarter. Standard Life Aberdeen plc now owns 5,743,738 shares of the medical instruments supplier’s stock worth $442,813,000 after buying an additional 3,146,868 shares during the last quarter. Finally, State of Tennessee Treasury Department lifted its holdings in Baxter International by 460.8% during the 4th quarter. State of Tennessee Treasury Department now owns 935,648 shares of the medical instruments supplier’s stock worth $61,584,000 after buying an additional 768,804 shares during the last quarter. Institutional investors own 86.12% of the company’s stock.

Shares of BAX traded up $0.27 on Wednesday, reaching $75.57. The stock had a trading volume of 1,656,910 shares, compared to its average volume of 3,013,375. The stock has a market cap of $38.76 billion, a P/E ratio of 24.78, a P/E/G ratio of 1.79 and a beta of 0.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.83 and a quick ratio of 1.30. Baxter International Inc has a twelve month low of $61.05 and a twelve month high of $82.25.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.08. The firm had revenue of $2.63 billion for the quarter, compared to analysts’ expectations of $2.61 billion. Baxter International had a return on equity of 20.04% and a net margin of 14.27%. Baxter International’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. Research analysts expect that Baxter International Inc will post 3.32 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Friday, June 7th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date is Thursday, June 6th. This is a positive change from Baxter International’s previous quarterly dividend of $0.19. Baxter International’s dividend payout ratio is currently 24.92%.

A number of analysts have issued reports on BAX shares. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Wednesday, April 24th. Barclays raised Baxter International from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $67.00 to $72.00 in a report on Friday, February 1st. Cowen set a $75.00 target price on Baxter International and gave the company a “hold” rating in a report on Monday, April 22nd. Wells Fargo & Co upped their price objective on Baxter International from $80.00 to $89.00 and gave the company an “outperform” rating in a research note on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. upped their price objective on Baxter International from $80.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, May 13th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Baxter International has a consensus rating of “Buy” and an average target price of $78.63.

In other Baxter International news, Director Thomas T. Stallkamp sold 1,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $75.16, for a total transaction of $75,160.00. Following the transaction, the director now owns 6,780 shares of the company’s stock, valued at approximately $509,584.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Third Point Llc sold 5,000,000 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $76.37, for a total value of $381,850,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,057,187 shares of company stock worth $386,297,619. Corporate insiders own 0.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Sundance Herald and is owned by of Sundance Herald. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://sundanceherald.com/2019/05/22/hartford-investment-management-co-has-4-74-million-position-in-baxter-international-inc-bax.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Story: Derivative

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply